Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery

European Journal of Pharmaceutical Sciences

Volumn 60, Issue , 2014, Pages 80-89

  Joshi, Garima ^a   Kumar, Abhinesh ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Factorial design; Gemcitabine HCl; Intestinal uptake; Nanoparticles; Oral delivery; Pharmacokinetics

Indexed keywords

GEMCITABINE; NANOCARRIER; POLYGLACTIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CACO 2 CELL LINE; CHEMICAL STRESS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTESTINE ABSORPTION; K562 CELL LINE; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BLOOD; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; INTESTINE; METABOLISM; ORAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL SURVIVAL; DEOXYCYTIDINE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; K562 CELLS; LACTIC ACID; MALE; POLYGLYCOLIC ACID; RATS, WISTAR;

EID: 84901944392     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.04.014     Document Type: Article

References (41)

1. V. Bharadwaj, and M.N.V. Ravikumar Polymeric Nanoparticles for Oral Delivery 2006 Taylor and Francis New York
2. V. Bhardwaj, D.D. Ankola, S.C. Gupta, M. Schneider, C.M. Lehr, and M.N. Kumar PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat Pharm. Res. 26 2009 2495 2503
3. S.B.C. Bolton Pharmaceutical Statistics: Practical and Clinical Applications fourth ed. 2004 Marcel Dekker USA
4. A.M. Calcagno, J.A. Ludwig, J.M. Fostel, M.M. Gottesman, and S.V. Ambudkar Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery Mol. Pharm. 3 2006 87 93
5. M.S. Cartiera, K.M. Johnson, V. Rajendran, M.J. Caplan, and W.M. Saltzman The uptake and intracellular fate of PLGA nanoparticles in epithelial cells Biomaterials 30 2009 2790 2798
6. K. Derakhshandeh, and S. Fathi Role of chitosan nanoparticles in the oral absorption of Gemcitabine Int. J. Pharm. 437 2012 172 177
7. Y. Dong, and S.S. Feng Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 6068 6076
8. EliLilly Summary of Product Characteristics: Gemcitabine. UK Prescribing Information 1997 Eli Lilly, Eli Lilly, Co
9. S.-S. Feng, L. Mei, P. Anitha, C.W. Gan, and W. Zhou Poly(lactide)- vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel Biomaterials 30 2009 3297 3306
10. A. Florence, and P.U. Jani Particulate delivery: the challenge of the oral route A. Rolland, Pharmaceutical Particulate Carriers: Therapeutic Applications 1993 Marcel Dekker New York 65 107
11. S.A. Galindo-Rodriguez, E. Allemann, H. Fessi, and E. Doelker Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies Crit. Rev. Ther. Drug Carrier Syst. 22 2005 419 464
12. 4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model J. Drug Target. 15 2007 445 453
13. M.L. Hans, and A.M. Lowman Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6 2002 319 327
14. W.H. Hao, J.J. Wang, S.P. Hsueh, P.J. Hsu, L.C. Chang, C.S. Hsu, and K.Y. Hsu In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation Cancer Chemother. Pharmacol. 71 2013 379 388
15. H. Hosseinzadeh, F. Atyabi, R. Dinarvand, and S.N. Ostad Chitosan-pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study Int. J. Nanomed. 7 2012 1851 1863
16. E.G.E.R.P.A. Ina Hubatsch Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2 2007
17. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials 21 2000 2475 2490
18. D.R. Kalaria, G. Sharma, V. Beniwal, and M.N. Ravi Kumar Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats Pharm. Res. 26 2009 492 501
19. X. Li, Y. Xu, G. Chen, P. Wei, and Q. Ping PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization- emulsification as the preparation method and in vitro/in vivo studies Drug Dev. Ind. Pharm. 34 2008 107 115
20. H. Luo, J. Li, and X. Chen Antitumor effect of N-succinyl-chitosan nanoparticles on K562 cells Biomed. Pharmacother. 64 2010 521 526
21. L. Mei, Z. Zhang, L. Zhao, L. Huang, X.L. Yang, J. Tang, and S.S. Feng Pharmaceutical nanotechnology for oral delivery of anticancer drugs Adv. Drug Deliv. Rev. 65 2013 880 890
22. B.P.C.B.F. Meneau, and P.C.M. Ollivon Interaction of an anticancer drug, gemcitabine, with phospholipid bilayers Acta Biomater. J. Therm. Anal. Calorim. 98 2009 19 28
23. J. Modi, G. Joshi, and K. Sawant Chitosan based mucoadhesive nanoparticles of ketoconazole for bioavailability enhancement: formulation, optimization, in vitro and ex vivo evaluation Drug Dev. Ind. Pharm. 39 2013 540 547
24. T. Musumeci, C.A. Ventura, I. Giannone, B. Ruozi, L. Montenegro, R. Pignatello, and G. Puglisi PLA/PLGA nanoparticles for sustained release of docetaxel Int. J. Pharm. 325 2006 172 179
25. L. Peltonen, J. Aitta, S. Hyvonen, M. Karjalainen, and J. Hirvonen Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles AAPS PharmSciTech 5 2004 E16
26. N.A. Peppas Analysis of Fickian and non-Fickian drug release from polymers Pharm. Acta Helv. 60 1985 110 111
27. B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira, and R. Neufeld Oral bioavailability of insulin contained in polysaccharide nanoparticles Biomacromolecules 8 2007 3054 3060
28. U. Seju, A. Kumar, and K.K. Sawant Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies Acta Biomater. 7 2011 4169 4176
29. T.H. Senanayake, G. Warren, X. Wei, and S.V. Vinogradov Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates J. Control. Release 167 2013 200 209
30. A. Trapani, J. Sitterberg, U. Bakowsky, and T. Kissel The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs Int. J. Pharm. 375 2009 97 106
31. W.J. Trickler, J. Khurana, A.A. Nagvekar, and A.K. Dash Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment AAPS PharmSciTech 11 2010 392 401
32. United States Pharmacopoeia 30 National Formulary 25, 2007. United Pharmacopoeial Convention Rockville.
33. M. Vandana, and S.K. Sahoo Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer Biomaterials 31 2010 9340 9356
34. S.A. Veltkamp, R.S. Jansen, S. Callies, D. Pluim, C.M. Visseren-Grul, H. Rosing, S. Kloeker-Rhoades, V.A. Andre, J.H. Beijnen, C.A. Slapak, and J.H. Schellens Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study Clin. Cancer Res. 14 2008 3477 3486
35. S.A. Veltkamp, D. Pluim, O. van Tellingen, J.H. Beijnen, and J.H. Schellens Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice Drug Metab. Dispos. 36 2008 1606 1615
36. K.Y. Win, and S.S. Feng Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 2713 2722
37. S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release 59 1999 299 307
38. S. Yee In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth Pharm. Res. 14 1997 763 766
39. Y. Yun, Y.W. Cho, and K. Park Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery Adv. Drug Deliv. Rev. 2012
40. Z. Zhang, L. Ma, S. Jiang, Z. Liu, J. Huang, L. Chen, H. Yu, and Y. Li A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor J. Control. Release 166 2013 30 37
41. S. Zhou, X. Feng, P. Kestell, J.W. Paxton, B.C. Baguley, and E. Chan Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4- acetic acid and its acyl glucuronide by human intestinal Caco-2 cells Eur. J. Pharm. Sci. 24 2005 513 524